Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
CirrhosisCongenital Heart Disease
Interventions
DRUG

Sildenafil

Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.

DRUG

Placebo

Placebo capsules matching study drug

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER